TI
NTLA icon

Tidal Investments’s Intellia Therapeutics NTLA Stock Holding History

Tidal Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$180K Buy
+14,076
New +$179K ﹤0.01% 2196

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tidal Investments's NTLA Position: Q1 2026 in Review

Tidal Investments opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 14,076 shares worth $180K. The stake represents ﹤0.01% of the portfolio and ranks #2196 among its holdings.

303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Tidal Investments held 14,076 shares of Intellia Therapeutics worth $180K as of Q1 2026.
  • Intellia Therapeutics was a new Tidal Investments position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Tidal Investments's portfolio in Q1 2026, its #2196 holding.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Tidal Investments's 13F filing for Q1 2026, filed 15 May 2026.